US firm De Novo Ventures closes $300m life science fundMenlo Park, California-based venture capital firm De Novo Ventures has closed its third venture fund, De Novo Ventures III, on $300m. The new fund will invest in medical device and in biotech companies with initial human clinical experience.
Fred Dotzler, a founder and managing director of De Novo Ventures, said, 'De Novo Ventures III builds upon the successful investment strategy of our first two funds.
'The new fund allows us to invest more capital in a given opportunity, and to support emerging companies from their early product development through initial marketing,' Dotzler continued.
De Novo Ventures focuses on investments in the Western US. The firm has $650m under management.
Copyright © 2006 AltAssets
Article is in the following categories:
Private Equity News» By News Type» Fund News
Private Equity News» By PE Sector» Venture/Growth
Private Equity News» By Region» North America» United States
Private Equity News» By News Type» Fund News
Private Equity News» By PE Sector» Venture/Growth
Private Equity News» By Region» North America» United States
